Under construction – not a live service
Sign in
Enrolling by invitationNo phase

Repairing windpipe narrowing in children using donor aortic tissue patches

Tests cryopreserved donor aortic patches to repair airway defects in infants and children.

Plain-language title generated from the registry record
Registry title: Feasibility of Tracheobronchial Reconstruction Using Allogenic Aortic Patch in Children

Key facts

Where
Taipei, TaiwanSee the site

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 0 and 18 years old?

Source: NCT07240259, who can take part

Where in Taiwan

  • Taiwan National Taiwan University HospitalTaipei, TaiwanNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
National Taiwan University Hospital
Trial code
NCT07240259
Record updated
17 August 2026
Original description
Feasibility and safety of repairing tracheal and bronchial defects in infants and children using cryopreserved donor aortic patches.Read full original descriptionShow less

Feasibility of Tracheobronchial Reconstruction Using Allogenic Aortic Patch in Children

Feasibility and safety of repairing tracheal and bronchial defects in infants and children using cryopreserved donor aortic patches.

Inclusion: Meeting any of the following conditions, and being unsuitable for standard end-to-end tracheal anastomosis or lacking sufficient native tracheal tissue for defect reconstruction:; Congenital tracheal malformations: including congenital tracheomalacia, congenital tracheobronchial anomalies, complete tracheal rings, etc., with severe clinical respiratory symptoms and recommended for treatment after evaluation; Acquired tracheal stenosis: including tracheal narrowing caused by disease, endotracheal intubation, or postoperative scar formation, with severe clinical respiratory symptoms and recommended for treatment after evaluation; Tracheal injury or tissue loss due to trauma or burns requiring surgical repair; Tracheal tumors: reconstruction of tracheal tissue after resection of benign or malignant tumors; The term "severe clinical respiratory symptoms" includes:; Dependence on mechanical ventilation for more than 1 month due to airway narrowing or defect, with inability to wean; Airway stenosis exceeding 50% (confirmed by bronchoscopy or CT imaging), accompanied by persistent stridor, inspiratory dyspnea, or suprasternal/substernal retractions, causing impairment of daily activities or feeding difficulties; Unilateral or bilateral lung atelectasis persisting for more than 1 month due to tracheal or bronchial stenosis, with no sign of recovery; Recurrent post-obstructive pneumonia (≥3 episodes) in one or both lungs caused by tracheal or bronchial stenosis, requiring hospitalization for treatment.

Exclusion: Malignant solid tumors with distant metastases that cannot be completely resected surgically or controlled with medication; Presence of severe immunodeficiency (e.g., congenital immunodeficiency, HIV infection, ongoing chemotherapy, or recovery period after bone marrow transplantation); Presence of major congenital diseases or chromosomal abnormalities (e.g., Trisomy 13, Trisomy 18) with extremely poor prognosis as assessed clinically; End-stage organ failure (e.g., persistent multiple organ failure, irreversible cardiopulmonary failure, or brain death); Inability to obtain legal informed consent from the lawful guardian; Locally invasive tracheal tumors that cannot be completely resected surgically.

ClinicalTrials.gov NCT07240259